{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:58:36Z","timestamp":1790657916313,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["214240"],"award-info":[{"award-number":["214240"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"DOI":"10.1007\/s10461-026-05315-y","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:28:04Z","timestamp":1790656084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-Reported Outcomes Among Virally Suppressed People Living with HIV Switching to Dolutegravir\/Lamivudine vs. Continuing Bictegravir\/Emtricitabine\/Tenofovir Alafenamide from the Randomized DYAD Study"],"prefix":"10.1007","author":[{"given":"Charlotte-Paige","family":"Rolle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Castano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vu","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Hinestrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"DeJesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"5315_CR1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv. Accessed December 11th, 2025."},{"key":"5315_CR2","unstructured":"Young B et al. October. Patient Experience and Views on Antiretroviral Treatment\u2014Findings from the Positive Perspectives Survey. Abstract 1393. Presented at the Infectious Disease Week (ID Week conference), 4\u20138 2017, San Diego, USA."},{"issue":"1","key":"5315_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10461-024-04479-9","volume":"29","author":"P Kumar","year":"2025","unstructured":"Kumar P, et al. Patient-reported outcomes after switching to a 2-drug regimen of fixed-dose combination dolutegravir\/lamivudine: 48-week results from the SALSA study. AIDS Behav. 2025;29(1):235\u201345.","journal-title":"AIDS Behav"},{"key":"5315_CR4","unstructured":"Noe S et al. 3-Year Outcomes for Dolutegravir (DTG) + Lamivudine (3TC) in ART-Naive and Pre-treated People Living with HIV-1 (PLHIV) in Germany: Real-world Data from the German URBAN Cohort. Abstract eP.A.072. Presented at 19th European AIDS Conference; October 18\u201321, 2023: Warsaw, Poland."},{"key":"5315_CR5","volume":"12","author":"M Duracinsky","year":"2025","unstructured":"Duracinsky M, et al. Patient-reported outcomes among people living with HIV switching to dual therapy with dolutegravir\/lamivudine: results from the PROBI study. Ther Adv Infect Dis. 2025;12:20499361251321728.","journal-title":"Ther Adv Infect Dis"},{"issue":"5","key":"5315_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s40271-018-0322-8","volume":"11","author":"D Wohl","year":"2018","unstructured":"Wohl D, et al. Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine. Patient. 2018;11(5):561\u201373.","journal-title":"Patient"},{"issue":"3","key":"5315_CR7","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jmii.2023.01.015","volume":"56","author":"LY Chen","year":"2023","unstructured":"Chen LY, et al. Patient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamide. J Microbiol Immunol Infect. 2023;56(3):575\u201385.","journal-title":"J Microbiol Immunol Infect"},{"issue":"5","key":"5315_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s13365-025-01270-x","volume":"31","author":"M Henderson","year":"2025","unstructured":"Henderson M, et al. Changes in cerebral function parameters in persons with HIV with symptoms of insomnia switching from dolutegravir- to bictegravir-based antiretroviral therapy. J Neurovirol. 2025;31(5):425\u201337.","journal-title":"J Neurovirol"},{"issue":"1","key":"5315_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.37201\/req\/080.2024","volume":"38","author":"D Cecchini","year":"2025","unstructured":"Cecchini D, et al. Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir\/emtricitabine\/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort. Rev Esp Quimioter. 2025;38(1):40\u20137.","journal-title":"Rev Esp Quimioter"},{"issue":"4","key":"5315_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/hiv.13593","volume":"25","author":"S Esser","year":"2024","unstructured":"Esser S, et al. Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts. HIV Med. 2024;25(4):440\u201353.","journal-title":"HIV Med"},{"issue":"7","key":"5315_CR11","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1080\/03007995.2025.2517692","volume":"41","author":"A Colson","year":"2025","unstructured":"Colson A, et al. Health care provider- and patient-reported outcomes for bictegravir\/emtricitabine\/tenofovir alafenamide versus other antiretroviral regimens: an observational survey in the United States (July 2021-March 2022). Curr Med Res Opin. 2025;41(7):1319\u201331.","journal-title":"Curr Med Res Opin"},{"key":"5315_CR12","doi-asserted-by":"crossref","unstructured":"Slim J et al. PAIRED- PAtient Reported Experienced and perceiveD benefit of treatment with dolutegravir\/lamivudine (DTG\/3TC): A diverse sample of people with HIV-1 (PWH) reporting high treatment satisfaction, good adherence, and high quality of life. Abstract P-537. Presented at Presented at: IDWeek 2024; October 16\u201319, 2024; Los Angeles, CA.","DOI":"10.1093\/ofid\/ofae631.736"},{"issue":"10","key":"5315_CR13","doi-asserted-by":"publisher","first-page":"ofae560","DOI":"10.1093\/ofid\/ofae560","volume":"11","author":"CP Rolle","year":"2024","unstructured":"Rolle CP, et al. Efficacy, safety, and tolerability of switching from bictegravir\/emtricitabine\/tenofovir alafenamide to dolutegravir\/lamivudine among adults with virologically suppressed HIV: the DYAD study. Open Forum Infect Dis. 2024;11(10):ofae560.","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 1","key":"5315_CR14","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/S0895-4356(01)00449-8","volume":"54","author":"AC Justice","year":"2001","unstructured":"Justice AC, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54(Suppl 1):S77\u201390.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"5315_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1524-4733.2006.00121.x","volume":"9","author":"A Woodcock","year":"2006","unstructured":"Woodcock A, Bradley C. Validation of the revised 10-item HIV treatment satisfaction questionnaire status version and new change version. Value Health. 2006;9(5):320\u201333.","journal-title":"Value Health"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-026-05315-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-026-05315-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-026-05315-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:28:05Z","timestamp":1790656085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-026-05315-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":15,"alternative-id":["5315"],"URL":"https:\/\/doi.org\/10.1007\/s10461-026-05315-y","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"18 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Charlotte-Paige Rolle has received research grants and honoraria from Gilead Sciences, ViiV Healthcare, and Merck Sharpe& Dohme during the conduct of this study. Dr. Federico Hinestrosa has received honoraria from Gilead Sciences, Merck, and AbbVie during the conduct of this study. Dr. Edwin DeJesus has received honoraria from Gilead Sciences during the conduct of this study.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}